

Leading Edge Trends in Medical Devices and Diagnostics: Innovation at Johnson and Johnson Ortho Clinical Diagnostics

Biomedical Engineering and CEIS Industrial Speaker Seminar

Kurt Schilling, Ph.D.
J&J Ortho Clinical Diagnostics

Tuesday, January 17th 9:00 – 10:00 am (note special time for BME Seminar)
URMC Lecture Room K307 (3-6408)
University of Rochester

Ortho Clinical diagnostics is a company in Johnson and Johnson's Medical Devices and Diagnostics division. OCD develops, manufactures, sells and supports diagnostic instruments and assays for: i. Clinical Chemistry & Immunodiagnostics across many diseases and conditions. ii. Transfusion Medicine, including donor screening and immuno-hematology, and iii. Companion Diagnostics to assist professionals and patients in selecting and/or predicting the safety and efficacy of drugs, surgeries and other medical treatments. In addition to our diagnostics products, OCD also produces extracorporeal photophoresis technology to treat diseases such as certain lymphomas and graft versus host disease. To support these businesses, we must generate sophisticated instruments with advanced hardware, software and automation technology. Furthermore, we must develop proprietary reagents, precisely coated surfaces and matrices, and robust new assays to meet regulatory requirements and to satisfy the diagnostic needs and evolving menus of our customers in hospital labs, reference labs, blood centers, and various decentralized points of care. Going forward, OCD must continue to deliver highly innovative technologies in order to respond to a number of technical and marketplace trends that are impacting our business. These include, but are not limited to, the emergence of personalized medicine, decentralized, point of care diagnostics, and preventative health and wellness; all are required for more cost effective, accessible and efficacious healthcare solutions.

This presentation will touch on some of the near and mid-term technologies driving our current and future platforms and that overlap with interests of investigators at the U of R. We will also discuss careers paths in innovation at OCD specifically, and J&J more broadly, and the training and preparation typically required.

[Map to URMC 3-6408](#)

Speaker Bio:

Kurt Schilling is currently VP, Assay R&D at Ortho Clinical Diagnostics (OCD), a Johnson & Johnson company, where he leads teams in Rochester, NY and Raritan, NJ involved in the development of medical diagnostic assays and platforms. Kurt joined J&J in 2005, as VP of Advanced Technologies, Consumer & Personal Products Worldwide, where he built and led a technology incubator. After that, he crossed over to J&J's Medical Devices and Diagnostics franchise, OCD, as VP, Business Incubation, to help build their Clinical Innovations group and lead the R&D efforts there.

Prior to joining J&J, Kurt spent 16 years with Unilever where he held various global R&D leadership positions in Skin, Oral and Hair Care in the US and Europe. Also while at Unilever, Kurt worked for three years in Corporate Strategy in London on a leadership team that established the company's new corporate mission, consumer "Vitality," as the center of gravity for the company, including building a new franchise, Health and Wellness, in Unilever's Foods division. His last position before going to J&J was as head of Unilever's US R&D laboratory in Edgewater, NJ.

Kurt obtained his B.S. in Biology from St. John Fisher College in Rochester, NY and his M.Sc. and Ph.D. in Microbiology and Immunology from the University of Rochester, School of Medicine and Dentistry.

This seminar is jointly sponsored by the Biomedical Engineering Department, the Center for Emerging and Innovative Sciences, and the Office of Research Alliances.